These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 7628874

  • 1. Engineering high affinity humanized anti-p185HER2/anti-CD3 bispecific F(ab')2 for efficient lysis of p185HER2 overexpressing tumor cells.
    Zhu Z, Lewis GD, Carter P.
    Int J Cancer; 1995 Jul 28; 62(3):319-24. PubMed ID: 7628874
    [Abstract] [Full Text] [Related]

  • 2. Engineering a humanized bispecific F(ab')2 fragment for improved binding to T cells.
    Rodrigues ML, Shalaby MR, Werther W, Presta L, Carter P.
    Int J Cancer Suppl; 1992 Jul 28; 7():45-50. PubMed ID: 1428403
    [Abstract] [Full Text] [Related]

  • 3. Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms.
    Link BK, Kostelny SA, Cole MS, Fusselman WP, Tso JY, Weiner GJ.
    Int J Cancer; 1998 Jul 17; 77(2):251-6. PubMed ID: 9650561
    [Abstract] [Full Text] [Related]

  • 4. Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene.
    Shalaby MR, Shepard HM, Presta L, Rodrigues ML, Beverley PC, Feldmann M, Carter P.
    J Exp Med; 1992 Jan 01; 175(1):217-25. PubMed ID: 1346155
    [Abstract] [Full Text] [Related]

  • 5. The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapy.
    Weiner GJ, Kostelny SA, Hillstrom JR, Cole MS, Link BK, Wang SL, Tso JY.
    J Immunol; 1994 Mar 01; 152(5):2385-92. PubMed ID: 8133049
    [Abstract] [Full Text] [Related]

  • 6. T cell activation and cytokine production in anti-CD3 bispecific antibody therapy.
    Belani R, Weiner GJ.
    J Hematother; 1995 Oct 01; 4(5):395-402. PubMed ID: 8581375
    [Abstract] [Full Text] [Related]

  • 7. Bispecific HER2 x CD3 antibodies enhance T-cell cytotoxicity in vitro and localize to HER2-overexpressing xenografts in nude mice.
    Shalaby MR, Carter P, Maneval D, Giltinan D, Kotts C.
    Clin Immunol Immunopathol; 1995 Feb 01; 74(2):185-92. PubMed ID: 7828373
    [Abstract] [Full Text] [Related]

  • 8. Trispecific F(ab')3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells.
    Tutt A, Stevenson GT, Glennie MJ.
    J Immunol; 1991 Jul 01; 147(1):60-9. PubMed ID: 1675655
    [Abstract] [Full Text] [Related]

  • 9. Identification of heavy chain residues in a humanized anti-CD3 antibody important for efficient antigen binding and T cell activation.
    Zhu Z, Carter P.
    J Immunol; 1995 Aug 15; 155(4):1903-10. PubMed ID: 7636241
    [Abstract] [Full Text] [Related]

  • 10. Anti-CD3 x anti-tumor F(ab')2 bifunctional antibody activates and retargets tumor-infiltrating lymphocytes.
    Chapoval AI, Nelson H, Thibault C.
    J Immunol; 1995 Aug 01; 155(3):1296-303. PubMed ID: 7636196
    [Abstract] [Full Text] [Related]

  • 11. High level secretion of a humanized bispecific diabody from Escherichia coli.
    Zhu Z, Zapata G, Shalaby R, Snedecor B, Chen H, Carter P.
    Biotechnology (N Y); 1996 Feb 01; 14(2):192-6. PubMed ID: 9636323
    [Abstract] [Full Text] [Related]

  • 12. In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody.
    Negri DR, Tosi E, Valota O, Ferrini S, Cambiaggi A, Sforzini S, Silvani A, Ruffini PA, Colnaghi MI, Canevari S.
    Br J Cancer; 1995 Oct 01; 72(4):928-33. PubMed ID: 7547242
    [Abstract] [Full Text] [Related]

  • 13. Further characterization of cytotoxic T cells generated by short-term culture of human peripheral blood lymphocytes with interleukin-2 and anti-CD3 mAb.
    Jacobs N, Greimers R, Mazzoni A, Trebak M, Schaaf-Lafontaine N, Boniver J, Moutschen MP.
    Cancer Immunol Immunother; 1996 Jul 01; 42(6):369-75. PubMed ID: 8830741
    [Abstract] [Full Text] [Related]

  • 14. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
    Scheffold C, Kornacker M, Scheffold YC, Contag CH, Negrin RS.
    Cancer Res; 2002 Oct 15; 62(20):5785-91. PubMed ID: 12384539
    [Abstract] [Full Text] [Related]

  • 15. Valency of CD3 binding and internalization of the CD3 cell-surface complex control T cell responses to second signals: distinction between effects on protein kinase C, cytoplasmic free calcium, and proliferation.
    Ledbetter JA, June CH, Martin PJ, Spooner CE, Hansen JA, Meier KE.
    J Immunol; 1986 Jun 01; 136(11):3945-52. PubMed ID: 3084650
    [Abstract] [Full Text] [Related]

  • 16. Engineering linear F(ab')2 fragments for efficient production in Escherichia coli and enhanced antiproliferative activity.
    Zapata G, Ridgway JB, Mordenti J, Osaka G, Wong WL, Bennett GL, Carter P.
    Protein Eng; 1995 Oct 01; 8(10):1057-62. PubMed ID: 8771187
    [Abstract] [Full Text] [Related]

  • 17. Chimeric bispecific OC/TR monoclonal antibody mediates lysis of tumor cells expressing the folate-binding protein (MOv18) and displays decreased immunogenicity in patients.
    Luiten RM, Warnaar SO, Sanborn D, Lamers CH, Bolhuis RL, Litvinov SV, Zurawski VR, Coney LR.
    J Immunother; 1997 Nov 01; 20(6):496-504. PubMed ID: 9409456
    [Abstract] [Full Text] [Related]

  • 18. Increased lysis of patient CD10-positive leukemic cells by T cells coated with anti-CD3 Fab' antibody cross-linked to anti-CD10 Fab' antibody.
    Oshimi K, Seto T, Oshimi Y, Masuda M, Okumura K, Mizoguchi H.
    Blood; 1991 Mar 01; 77(5):1044-9. PubMed ID: 1825287
    [Abstract] [Full Text] [Related]

  • 19. Localization of monoclonal antibody G250 and bispecific monoclonal antibody CD3/G250 in human renal-cell carcinoma xenografts: relative effects of size and affinity.
    van Dijk J, Zegveld ST, Fleuren GJ, Warnaar SO.
    Int J Cancer; 1991 Jul 09; 48(5):738-43. PubMed ID: 1830033
    [Abstract] [Full Text] [Related]

  • 20. [The enhancement of cytolytic activity in lymphokine activated killer cells using bispecific F(ab')2].
    Azuma A.
    Nihon Ika Daigaku Zasshi; 1991 Dec 09; 58(6):663-72. PubMed ID: 1663120
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.